Seyer to promote Aggrastat in Puerto Rico


Medicure Pharma has entered into an agreement with Seyer Pharmatec for the sale and marketing of Aggrastat (tirofiban) within the Commonwealth of Puerto Rico. Under the terms of the agreement, the Seyer sales force will launch its promotional efforts for the product in January 2013.

Aggrastat, in combination with heparin, is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous transluminal coronary angioplasty or atherectomy. In this setting, Aggrastat has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischaemia/repeat cardiac procedure. The drug has been studied in a setting that included aspirin and heparin.



Agreement Information:
Agreement Status: New Date Announced: 5 Nov 2012
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Commercialisation
Generic / Brand Name: Aggrastat tirofiban
Therapeutic Area: Cardiovascular System
Indication: Acute coronary syndrome
Techonology/Field: N/A



Agreement Information:
Agreement Status: New Date Announced: 5 Nov 2012
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Commercialisation
Generic / Brand Name: Aggrastat tirofiban
Therapeutic Area: Cardiovascular System
Indication: Acute coronary syndrome
Techonology/Field: N/A
This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Canada, Puerto Rico, Canada, Puerto Rico, Puerto Rico

Related products in our Store...

Check out our most popular reports below or view more in our store